Argus raises target for Halozyme Therapeutics stock to USD 127

Published on 10/01/2026 at 12:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue hit USD 481.00 million, up 47.70 percent. Halozyme Therapeutics stock costs EUR 98.14 on October 1, 2026 versus EUR 97.59.

HALO, US40637H1095, Illustration mit AI erstellt.

Halozyme Therapeutics stock (ISIN US40637H1095) was trading at EUR 98.14 at Lang & Schwarz on October 1, 2026 at 12:47 p.m. CEST, up 0.56 percent versus the prior close of EUR 97.59. Argus raised its price target for the company to USD 127.00 in a report dated September 23, 2026, according to Yahoo Finance.

Argus sets a USD 127 target

The new Argus target gives analysts' valuation work a clear reference point in US dollars, while the Lang & Schwarz quote provides the euro perspective for investors in Germany. The report identifies Halozyme as a healthcare company and sets its target at USD 127.00.

MarketBeat reported on September 30, 2026, that Halozyme had nine buy ratings, three holds and one sell among 13 analysts. The average 12-month target was USD 91.20, below Argus's USD 127.00 target, showing a wide spread in published expectations.

Second-quarter revenue reaches USD 481 million

Halozyme's second-quarter 2026 revenue reached USD 481.00 million, up 47.70 percent from the prior year, according to MarketBeat in its September 30, 2026 report. The figure exceeded the cited USD 402.28 million consensus estimate by USD 78.72 million.

The same report put quarterly earnings per share at USD 2.28 versus USD 1.79 expected, a USD 0.49 difference. Halozyme's fiscal 2026 earnings guidance stood at USD 8.65-9.00 per share, giving the current valuation a forward earnings reference.

Stock remains below its yearly high

HALO's market capitalization was USD 13.1 billion as of September 30, 2026. Its 52-week range was USD 61.23 to USD 116.85, placing the Lang & Schwarz euro quote below the corresponding upper boundary after currency conversion.

Halozyme develops subcutaneous drug-delivery technologies through its ENHANZE platform. The company's investor-relations page describes a technology designed to turn hours-long infusions into injections delivered in seconds or minutes, according to Halozyme.

Next report date is November 9

TradingView lists November 9, 2026, as Halozyme's next report date for the third quarter of 2026. That date follows the second-quarter report and gives investors the next scheduled point for testing revenue growth and the fiscal-year outlook.

HALO trades at EUR 98.14

HALO was trading at EUR 98.14 at Lang & Schwarz on October 1, 2026 at 12:47 p.m. CEST, plus 0.56 percent versus the Lang & Schwarz prior close of EUR 97.59 on September 30, 2026.